aro-mapt — Initial data
2026
Emerging CNS pipeline with systemic delivery via SC administration: early ARO-MAPT data presented in 2026Source filing
ARWR biotech catalysts & pipeline
ARROWHEAD PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
ARO-DIMER-PA — Initial data
2H 2026
ARO-DIMER-PA targeting PCSK9 and APOC3 first clinical readout in 2H 2026Source filing
REDEMPLO (plozasiran) — NDA/BLA submission
Late 2026
Acquired a U.S. Food and Drug Administration (FDA) priority review voucher, which the company intends to use with its upcoming plozasiran sNDA submission, anticipated before the end of 2026, to potentially expand the approved indication to include patients with severe hypertriglyceridemia (sHTG).Source filing
zodasiran — Topline data
mid-2027
The Company anticipates that YOSEMITE will be completed in mid-2027 and, pending successful clinical results, intends to seek regulatory approval in multiple geographies thereafter.Source filing